New Therapeutic Options Enhance Breast Cancer Treatment: ASCO Reports
Three Cancer Centers Test Targeted Therapy For Resistant Acute Myelogenous Leukemia
Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer
Study Finds No Link Between Pill And Breast Cancer Risk
Vasectomy Doesn’t Increase Prostate Cancer Risk
Drug Slows Tumor Growth In Metastatic Kidney Cancer
STI-571 Effects Are Lasting Against GI Stromal Tumors
Monoclonal Antibody Improves AML Response To Therapy
Protocols Approved During the Month of June 2002
Trending Stories
- NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit - Bhattacharya cancels NIH all-hands meeting
- Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies - In the Headlines: “There’s no one to stand up for NCI right now.”
- George Weiner: Cancer centers are special, as are site visits in CCSG review